Financials RespireRx Pharmaceuticals Inc.
Equities
RSPI
US7612273059
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00425 USD | +16.44% |
|
+48.28% | +377.78% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 3.001 | 2.332 | 0.4045 | 2.067 | 1.127 | 0.2888 |
Enterprise Value (EV) 1 | 4.065 | 3.549 | 2.022 | 3.75 | 3.204 | 2.997 |
P/E ratio | -0.64 x | -0.84 x | -0.18 x | -0.13 x | -0.29 x | -0.06 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -0.96 x | -1.63 x | - | - | - | - |
EV / FCF | 5.28 x | -18 x | 10.9 x | -3.4 x | -17.4 x | 7.71 x |
FCF Yield | 19% | -5.57% | 9.14% | -29.4% | -5.75% | 13% |
Price to Book | -0.8 x | -0.44 x | -0.06 x | -0.26 x | -0.11 x | -0.02 x |
Nbr of stocks (in thousands) | 263 | 359 | 405 | 71,271 | 96,341 | 1,25,544 |
Reference price 2 | 11.40 | 6.500 | 0.9999 | 0.0290 | 0.0117 | 0.002300 |
Announcement Date | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 | 17/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -4.242 | -2.171 | - | - | - | - |
EBIT 1 | -4.247 | -2.177 | -1.737 | -3.315 | -2.559 | -1.579 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -4.291 | -2.592 | -2.115 | -4.301 | -3.145 | -2.103 |
Net income 1 | -4.291 | -2.592 | -2.115 | -4.301 | -3.145 | -2.103 |
Net margin | - | - | - | - | - | - |
EPS 2 | -17.75 | -7.734 | -5.411 | -0.2221 | -0.0399 | -0.0357 |
Free Cash Flow 1 | 0.7705 | -0.1976 | 0.1848 | -1.101 | -0.1843 | 0.389 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 | 17/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 1.06 | 1.22 | 1.62 | 1.68 | 2.08 | 2.71 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -0.2508 x | -0.5603 x | - | - | - | - |
Free Cash Flow 1 | 0.77 | -0.2 | 0.18 | -1.1 | -0.18 | 0.39 |
ROE (net income / shareholders' equity) | 87.1% | 51.4% | 32.1% | 55.5% | 34.8% | 19.2% |
ROA (Net income/ Total Assets) | -1,239% | -853% | -1,280% | -3,178% | -1,089% | -853% |
Assets 1 | 0.3465 | 0.3039 | 0.1652 | 0.1354 | 0.2889 | 0.2466 |
Book Value Per Share 2 | -14.30 | -14.90 | -17.90 | -0.1100 | -0.1000 | -0.0900 |
Cash Flow per Share 2 | 0.2800 | 0.0900 | 0.0400 | 0 | 0 | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 17/04/18 | 16/04/19 | 14/04/20 | 15/04/21 | 15/04/22 | 17/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+377.78% | 2.94M | |
+16.17% | 122B | |
+19.75% | 113B | |
+18.95% | 26.49B | |
-24.14% | 19.4B | |
-19.03% | 16.24B | |
-20.89% | 15.4B | |
-46.14% | 15.15B | |
+63.26% | 14.93B | |
+4.44% | 13.52B |
- Stock Market
- Equities
- RSPI Stock
- Financials RespireRx Pharmaceuticals Inc.